Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) will discontinue clinical development of Ace-ER after disappointing Phase 3 study results. The stock price plunged $7.83 to close at $51.02.
Ultragenyx Pharmaceuticals discontinues Ace-ER development
August 23, 2017 at 18:48 PM EDT
